Trxade Group, Inc. — Form 10-Q Summary
Entity note: The filing identifies the registrant as Trxade Group, Inc., not Scienture Holdings, Inc. It reports the quarter and six months ended June 30, 2019; financial statements are unaudited.
Business context
Trxade operates a pharmaceutical business-to-business marketplace and also owns a pharmaceutical wholesaler, Community Specialty Pharmacy, and Alliance Pharma Solutions. Community Specialty Pharmacy was acquired in October 2018. The company reported more than 8,500 registered pharmacy members.
Financial results and condition
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $1.916 million | $0.838 million | $3.429 million | $1.691 million |
| Gross profit | $1.163 million | $0.838 million | $2.310 million | $1.691 million |
| Gross margin | 60.7% | 100.0% | 67.4% | 100.0% |
| Operating income | $132,705 | $31,446 | $304,464 | $130,174 |
| Net income | $57,981 | $20,513 | $183,210 | $102,782 |
Revenue rose 129% for Q2 and 103% for the first half, with management attributing the increase primarily to Community Specialty Pharmacy. The prior-period statements reported no cost of sales, so the gross-margin comparisons are affected by the changed business mix. First-half operating expenses were $2.005 million, including $99,990 of stock-option expense; interest expense was $33,432 and the SyncHealth equity-method investment generated an $87,822 loss. Basic EPS was reported as $0.00 for Q2 and $0.01 for the first half.
At June 30, cash was $540,034, down from $869,557 at year-end. Current assets were $1.952 million and current liabilities $1.085 million, implying working capital of $867,107. Total liabilities were $2.338 million, including $662,552 of related-party notes and $811,165 of operating lease liabilities. Shareholders’ equity was $1.340 million.
For the first half, operating cash flow was negative $79,689, versus positive $146,456 a year earlier; the company cited inventory purchases and higher receivables. Investing cash outflow was $250,000 for SyncHealth, and cash declined by $329,523. The filing does not provide a clear standalone quarterly cash-flow figure.
Changes, outlook, risks, and unusual items
- The October 2018 pharmacy acquisition materially expanded revenue and added operating costs, including rent and employee compensation.
- The company invested $250,000 for an interest in SyncHealth MSO and recorded a first-half equity loss of $87,822. Further ownership transfers and potential stock consideration are described in the agreement.
- In February 2019, $211,983 of convertible debt and accrued interest was converted into 423,966 shares. A July 10 post-period private placement sold 2 million shares at $0.50 for $1 million gross proceeds.
- Management estimated approximately $3.5 million of operating expenses and working-capital requirements for the next 12 months and said additional funding would be needed. It cautioned that operating cash generation and access to financing were not assured. No revenue or earnings guidance was provided.
- Two related-party convertible notes totaling $140,000 were current at quarter-end. One $100,000 note was extended in July to October 15, 2019; the other $40,000 note was due August 8, 2019.
- Management concluded disclosure controls and procedures were not effective. It reported no material change in internal control over financial reporting during the quarter. The filing reported no legal proceedings, no off-balance-sheet arrangements, and no change in risk factors from the latest Form 10-K.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
- Assess cash runway, working-capital needs, and whether the post-quarter $1 million financing is sufficient relative to the stated $3.5 million requirement.
- Review SyncHealth’s current ownership, transfer milestones, revenue quotas, and potential share issuance or dilution.
- Check the status and repayment or conversion terms of related-party notes and lease obligations.
- Follow management’s remediation of ineffective disclosure controls and verify the company’s reported results against subsequent filings.